<?xml version="1.0" ?>
<tei>
	<teiHeader>
		<fileDesc xml:id="55012987"/>
	</teiHeader>
	<text xml:lang="en">
		<front>
<lb/>
	<byline>
	<affiliation>European Medicines Agency<lb/></affiliation>
	</byline>

	<address>7 Westferry Circus, Canary Wharf, London, E14 4HB, UK<lb/></address>

	<phone>Tel. (44-20) 74 18 84 00 Fax (44-20) 74 18 84 16<lb/> </phone>

	<email>E-mail: mail@emea.europa.eu</email>

	<ptr type="web">http://www.emea.europa.eu<lb/></ptr>

	<date>London, 19 February 2009<lb/></date>

	<idno>Doc. Ref.: EMEA/135697/2009<lb/></idno>

	<docTitle>
	<titlePart>CHMP ASSESSMENT REPORT<lb/> FOR<lb/> Exalief<lb/> </titlePart>
	</docTitle>

	<note type="other">International Nonproprietary Name: eslicarbazepine acetate<lb/> </note>

	<idno>Procedure No. EMEA/H/C/000987<lb/> </idno>

	<note type="other">Assessment Report as adopted by the CHMP with<lb/> all information of a commercially confidential nature deleted.
	<lb/></note>

	<note type="page">Page 2 of 80<lb/></note>
	
	<note type="other">TABLE OF CONTENTS<lb/></note>

		</front>
	</text>
</tei>
